Amgen Announces Positive Phase 3 Results for Dazodalibep in Sjögren’s Disease
Amgen said its Phase 3 trial of dazodalibep showed clinically meaningful improvements in systemic disease activity.
Story updates
01:04:03 PM UTC
SquawkNews
Amgen reported both dazodalibep dosing regimens significantly reduced systemic disease activity vers